A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Nivolumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Placebo Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials